

RESEARCH ARTICLE

Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children

Sara Guillén^{1☯*}, Luis Prieto^{2☯}, Santiago Jiménez de Ory^{3☯}, María Isabel González-Tomé^{2‡}, Pablo Rojo^{2‡}, María Luisa Navarro^{4‡}, María José Mellado^{5‡}, Luis Escosa^{5‡}, Talía Sainz^{5‡}, Laura Francisco^{6‡}, María Ángeles Muñoz-Fernández^{3‡}, José Tomás Ramos^{6☯}, On behalf of CoRISpe (Cohorte Nacional de VIH pediátrica de la RED RIS)¹


1 Department Pediatrics, Hospital Universitario de Getafe, Madrid, Spain, **2** Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain, **3** Department of Immunology, Hospital Universitario Gregorio Marañón, Madrid, Spain, **4** Department of Pediatrics, Hospital Universitario Gregorio Marañón, Madrid, Spain, **5** Department of Pediatrics, Hospital Universitario La Paz, Madrid, Spain, **6** Department of Pediatrics, Hospital Clínico Universitario San Carlos, Madrid, Spain

☯ These authors contributed equally to this work.

‡ These authors also contributed equally to this work.

1^{||} Membership of the CoRISpe (Cohorte Nacional de VIH pediátrica de la RED RIS) is provided in the acknowledgments.

* sguillenmartin@hotmail.com



OPEN ACCESS

Citation: Guillén S, Prieto L, Jiménez de Ory S, González-Tomé MI, Rojo P, Navarro ML, et al. (2019) Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children. PLoS ONE 14(8): e0220552. <https://doi.org/10.1371/journal.pone.0220552>

Editor: Giuseppe Vittorio De Socio, Azienda Ospedaliera Universitaria di Perugia, ITALY

Received: November 6, 2018

Accepted: July 18, 2019

Published: August 5, 2019

Copyright: © 2019 Guillén et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data is within the paper.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Background

Combination antiretroviral therapy (cART) is associated with marked immune reconstitution. Although a long term viral suppression is achievable, not all children however, attain complete immunological recovery due to persistent immune activation. We use CD4/CD8 ratio like a marker of immune reconstitution.

Methods

Perinatal HIV-infected children who underwent a first-line cART, achieved viral suppression in the first year and maintained it for more than 5 years, with no viral rebound were included. Logistic models were applied to estimate the prognostic factors, clinical characteristics at cART start, of a lower CD4/CD8 ratio at the last visit.

Results

146 HIV-infected children were included: 77% Caucasian, 45% male and 28% CDC C. Median age at cART initiation was 2.3 years (IQR: 0.5–6.2). 42 (30%) children received mono-dual therapy previously to cART. Time of undetectable viral load was 9.5 years (IQR: 7.8, 12.5). 33% of the children not achieved CD4/CD8 ratio >1. Univariate analysis showed an association between CD4/CD8 <1 with lower CD4 nadir and baseline CD4; older age at diagnosis and at cART initiation; and a previous exposure to mono-dual therapy. Multivariate analysis also revealed relationship between CD4/CD8 <1 and lower CD4 nadir (OR:

1.002, CI 95% 1.000–1.004) as well as previous exposure to mono-dual therapy (OR: 0.16, CI 95% 0.003–0.720).

Conclusions

CD4/CD8 >1 was not achieved in 33% of the children. Lower CD4 nadir and previous exposure to suboptimal therapy, before initiating cART, are factors showing independently association with a worse immune recovery (CD4/CD8 < 1).

Introduction

The combination antiretroviral therapy (cART) has led not only to a decrease in HIV viral load but also to the recovery of CD4 T cell count and ultimately to the clinical improvement of HIV-infected children [1, 2]. Plasma viremia suppression by cART is generally associated with improvements in the immunological condition of patients, but some children fail to achieve normalization of CD4 T cell count. [3]

Various mechanisms such as immune activation, on-going HIV replication and deficient thymus output are associated with impaired immunological response to treatment in adults. [4] In vertically HIV-1 infected children, the infection is acquired when the immune system is still immature and the thymus is activated to produce new naïve T cells. [2] Highly active thymus in early childhood may contribute to a better immune reconstitution if ART is initiated early in life. [5] With the increase in age, the recovery through the naïve pool is progressively damaging, hence early treatment is the key for immune reconstitution. [6] However, other studies suggest that the recovery of the thymic function is age-independent and it is related to peripheral CD4 cell depletion as well as HIV-1 suppression. [7]

Little is known about long term immune recovery in HIV-infected children on cART. Immune recovery has been associated with earlier age, higher CD4 cell count and CD4 nadir at cART initiation, whereas, severe immunosuppression is associated with an impaired CD4 recovery. [8, 9, 10, 11] cART significantly reduces the degree of immune activation and detectable viral load aggravates immune senescence in children. [12, 13]

Restoration of CD4/CD8 ratio requires both CD4 cell recovery and normalization of the CD8 count. CD4/CD8 ratio has been associated with T cell activation, despite long term viral suppression in both, children and adults, as well as evidence to support that this imbalance has clinical importance in children. [14, 15, 16] A persistently low CD4/CD8 ratio despite viral control reflects a higher risk of morbidity in HIV-infected adults. [17] In addition, CD4/CD8 ratio has been described as a predictor of CD4 response in HIV-1-infected adults. [18] So we used CD4/CD8 ratio as a better predictor of long term immune recovery, since CD4 does not predict immune activation.

The aim of this study was to study possible risk factors of not achieving a CD4/CD8 >1 in children with long term immune reconstitution and maintained undetectable viral load, in order to determine possible risk factors that could affect the immunological response to cART.

Materials and methods

Study design

IRB (Hospital de Getafe) approved the study. This is a multicenter observational study, within the Pediatric branch of the National AIDS Research Network of Spain (CoRISpe). 383

perinatal HIV-infected children were in follow up in this cohort when the study was conducted. We included children who met the following inclusion criteria: 1) were receiving cART when the study was conducted; 2) who underwent first-line cART, had evidence of virological suppression within the first year after cART initiation; 3) had subsequent maintenance for more than 5 years with no viral rebound longer than 3 months at each time or at least until last observation before transition to adult units. 146 children were analyzed. The study was conducted from 1997 to December 2015.

Data were retrospectively collected from clinical visits performed every 3 months since cART initiation. A duly signed informed consent was obtained from the parents or legal guardians of patients <12 years and direct informed assent from patients aged ≥ 12 years in order to participate in CoRISpe.

Definitions

First-line cART refers to those patients that had not taken any cART regimen previously, but could have taken mono or dual antiretroviral therapy. Viral suppression was defined as <400 HIV-RNA copies/ml.

Patients with a CD4/CD8 ratio >1 at last clinical visit, were considered to have achieved immune recovery and patients with a CD4/CD8 < 1 were considered not to reach immune recovery. We studied possible risk factors at baseline of not achieving a CD4/CD8 >1 at last visit, comparing both groups.

We considered baseline time when children started first line of cART.

Statistics

All continuous variables were expressed as median (IQR), and categorical variables as frequency of distribution and rates. Differences between categorical variables were analysed using the Chi square test and Fisher exact test. T student test was used to compare continuous variables. A multivariable logistic regression model was used to analyse the relationship between immune recovery and variables showing statistical significance in univariate analysis. Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, NY: IBM Corp). A P value of 0.05 was considered statistically significant.

Results

Clinical characteristics at baseline

A total of 146 HIV-infected children were enrolled in this study. Results are shown in [Table 1](#). In general, 81 (55%) were female and 47 (33%) were non Caucasian. Their median age at diagnosis was 0.6 years (IQR: 0.2, 2.1), the median age at cART initiation was 2.3 years (IQR: 0.5, 6.2) and 19 (28%) were on CDC stage C. Mono-dual therapy was taken by 42 (30%) patients previous to cART, the rest of patients were naïve. The median of CD4 nadir was 457 cells/mm³ (IQR: 269, 678) and the median of CD4 cells and CD4% at baseline were 901 (IQR: 470, 1800) cells/mm³ and 26% (IQR: 16, 35), respectively. The median CD4/CD8 ratio at baseline was 0.6 (IQR: 0.3, 1.2).

Follow up and immune recovery

As shown in [Table 1](#), the median follow up period of patients in this study was more than 10 years, with a median duration of cART of 9.8 years (IQR: 8.1, 13.2) and a median of 2 different cART regimens taken per patient (IQR: 2, 4). The patients remained with undetectable viral

Table 1. Baseline clinical characteristics of subjects.

Characteristics	Total
N	146
Female gender, n (%)	81 (55%)
Age at diagnosis (years), median (IQR)	0.6 (0.2, 2.1)
Age at HAART initiation, median (IQR)	2.3 (0.5, 6.2)
Age at the last visit, median (IQR)	14.4 (10.6, 18.1)
Ethnicity, n (%)	
Caucasian	97 (67%)
Non Caucasian	47 (33%)
Clinical stage at baseline, n (%)	
N/A	78 (53.5%)
B	40 (27.5%)
C	19 (28%)
Nadir CD4 (cells/mm ³), median (IQR)	457 (269, 678)
Nadir CD4%, median (IQR)	19 (11, 25)
Prior history of ART, n (%)	
Mono or dual ART	42 (30%)
Naïve	104 (70%)
cART	
Total n° of ART regimens, median (IQR)	3 (2, 5)
Total n° of cART regimens, median (IQR)	2 (2, 4)
Duration of cART (years), median (IQR)	9.8 (8.1, 13.2)
Baseline CD4 and CD8	
CD4 (cells/mm ³) at baseline, median (IQR)	901 (470, 1800)
CD4% at baseline, median (IQR)	26 (16, 35)
CD8 (cells/mm ³) at baseline, median (IQR)	1398 (861, 1964)
CD8% at baseline, median (IQR)	37 (28, 40.5)
CD4/CD8 ratio at baseline, median (IQR)	0.6 (0.3, 1.2)
Viral load	
Viral load at baseline (log ₁₀), median (IQR)	4.88 (4.12, 5.67)
Time of undetectable viral load, median (IQR)	9.5 (7.8, 12.5)

<https://doi.org/10.1371/journal.pone.0220552.t001>

load for 9.5 years (IQR: 7.8, 12.5). 63 of 146 children (43%) had a viral blip in the follow up. Median age at last observation was 14.4 years (IQR: 10.6, 18.1).

In general, the median CD4 count and percentage at last visit were 878 cells/mm³ (IQR: 672, 1085) and 38% (IQR: 33, 43), respectively, and the median CD4 /CD8 ratio was 1.2 (IQR: 0.9, 1.6).

Factors associated with not immune recovery

At last clinical visit, immune recovery (CD4/CD8 ratio >1) was not achieved in 48/146 (33%) children. Results are shown in Table 2.

When comparing both groups of patients, the significant predictors of not immune recovery by univariate analyses were lower CD4 nadir, lower CD4 count and percentage, lower CD4/CD8 ratio and higher CD8 percentage at baseline.

An older age at HIV diagnosis and cART initiation was also associated to a unsuccessful immune response. Being exposed to mono-dual therapy was also a predictor for worse immune recovery.

Table 2. Prognostic factors of subjects by immune recovery.

Characteristics	Univariate analysis			Multivariate analysis	
	Non Immune recovery CD4/CD8 < 1	Immune recovery CD4/CD8 > 1	p	Adjusted difference Odds ratio (95% CI)	p
N	48	98	-		
Female gender, n (%)	26 (32)	55 (68)	0,8		
Age at diagnosis (years), median (IQR)	1.4 (0.2, 3.6)	0.5 (0.1–1.8)	0.03	0.957 (0.745–1.231)	0.7
Age at HAART initiation, median (IQR)	5.6 (2.1, 8.06)	1.3 (0.3, 4.4)	< 0.001	0.951 (0.789–1.147)	0.6
Age at the last visit, median (IQR)	16.8 (13.4, 18.7)	13.5 (10.1, 17.8)	0.01		
Ethnicity, n (%)					
Caucasian	33	64	0.7		
Non Caucasian	14	33			
Clinical stage at baseline, n (%)					
N/A	25	53	0.6		
B	12	26			
C	10	18			
Nadir CD4 (cells/mm ³), median (IQR)	323 (153, 503)	543 (350, 764)	< 0.001	1.002 (1.000–1.004)	0.01
Nadir CD4%, median (IQR)	14.5 (8–21)	21.5 (14–28)	< 0.001		
Prior history of ART, n (%)					
Mono or dual ART	23	19	0.001	0.164 (0.037–0.725)	0.01
Naïve	25	79			
cART median (IQR)					
Total n° of ART regimens	4 (3, 5)	3 (2, 4)	0.2		
Total n° of cART regimens	2 (2, 3)	3 (2, 4)	0.5		
Duration of cART (years)	9.5 (7.4–12)	10.6 (8.2–13.8)	0.1		
Baseline CD4 and CD8 median (IQR)					
CD4 (cells/mm ³) at baseline	563 (201, 1039)	1264 (735, 2299)	<0.001	1.000(0.999–1.001)	0.5
CD4% at baseline	20 (8, 28)	32 (20, 38)	<0.001		
CD8 (cells/mm ³) at baseline	1411 (866, 1933)	1375 (861–1964)	0.61		
CD8% at baseline	48 (38–60)	35 (22–44)	<0.001		
CD4/CD8 ratio at baseline	0.4 (0.1, 0.6)	0.9 (0.5, 1.6)	<0.001	1.777 (0.782–4.035)	0.1
Viral load median (IQR)					
Viral load at baseline (log ₁₀)	4.8 (4, 5.4)	4.9 (4.2, 5.7)	0.4		
Time of undetectable viral load	9.1 (7.7, 11.4)	9.8 (7.9–12.6)	0.2		

<https://doi.org/10.1371/journal.pone.0220552.t002>

In multivariate analysis, a CD4/CD8 ratio < 1 was associated with lower CD4 nadir, (OR: 1.002, CI 95% 1.000–1.004) as well as previous exposure to mono-dual therapy (OR: 0.16, CI 95% 0.003–0.720).

Discussion

This study described the immune response in HIV-infected children treated with long term cART, and reported an independent association between the lower CD4 nadir of patients and the exposure to suboptimal ART regimens with a CD4/CD8 ratio <1, which represents a unsuccessful immune recovery.

CD4/CD8 > 1 was not achieved in our study in 33% of the patients. Although the majority of the studies in children define immune recovery as a CD4 percentage greater than 25% [19, 20], we used CD4/CD8 ratio as a better predictor of long term immune recovery, since CD4 does not predict immune activation. Recently, the CD4/CD8 ratio has been described as a marker of immune activation in virologically suppressed HIV adults and children patients.

[14, 15, 16, 21] Moreover, the CD4/CD8 ratio can contribute to the immunological evaluation of treated patients in a long-term follow-up and may be applied for monitoring both immune dysfunction and viral reservoir size in virologically suppressed HIV-positive adults. [22]

The median follow-up period of patients on cART in this study was nearly 10 years. To our knowledge, this study is the largest to date in terms of long term follow-up period on immune recovery in children. Other studies, however, showed a follow-up period of 5 to 7 years in naïve children and a follow-up period of 6 years in pre-treated children. [1, 19, 20]

We did not find any association between cART duration or number of regimens and immune recovery, although was nearly significant (p value was 0.1 and p 0.2 respectively), probably due to our small sample size. Both groups received a long term therapy with a median duration of nearly 10 years with various regimens. A longer duration of cART was an independent predictor of immune recovery in a study from Thailand. [19] We did not compare the immune recovery between the different antiretroviral drugs used, but it was described that in adults, normalization of the CD4/CD8 ratio above a clinically meaningful threshold may be dependent on the drug class used. [23]

Receiving suboptimal treatment such as mono-dual therapy could lead to an impaired immune recovery, because these therapies were not efficacy to achieve persistent undetectable viral load and immune recovery. So initiating cART, after severe immunosuppression has occurred, is detrimental for the restoration of the CD4 cell count. A third of the patients in our study had previously received mono or dual therapy and, therefore, achieved a lower CD4/CD8 ratio at the end of the study compared to naïve patients. Our results are consistent with those in a study covering a similar population, except that all subjects had previously received mono or dual therapy where they found a significant association between not reaching CD4% > 25% during follow-up and the duration of antiretroviral therapy before cART. [1]

A worse immune recovery in our study, while comparing the two groups, was associated with older age at diagnosis and at cART initiation in univariate analysis. Our interpretation to this, as reported in previous studies [8, 19, 24, 25, 26], is that early initiation of cART may improve the immune recovery. However, these associations in our study were not maintained in multivariate analysis. Data from few studies suggested that the immune recovery is independent of the age at cART initiation. [9, 27] Better viral suppression but poorer immunological responses have been described in older individuals compared to children. [10] The median time to achieve immunological response (CD4 > 30%) has been described to be shorter in children younger than two years, irrespective of pre-cART CD4 counts and the time to immune recovery, and it increased progressively in older children. [25]

Initiation of cART after severe immunosuppression was described as ineffective in several studies for a normal CD4 count recovery. [1, 11] A study conducted in the United States showed that children who started ART and who had a higher nadir CD4% were more likely to achieve a higher CD4%. [8] Two studies conducted in Thailand showed that higher baseline CD4% was associated with better achievement of immune recovery. [28, 29] These results show consistency with the ones observed in our cohort, as univariate analysis showed that patients who had worse immune recovery had a lower CD4 nadir and a lower CD4 count at baseline, although, only the CD4 nadir remained independently associated to immune reconstitution in multivariate analysis. Other studies, have described that patients under greater immunosuppression had the largest CD4 increase, but only a minority of these patients achieved CD4 > 25%. [20, 24]

So we can say, like in other studies in adults that early initiation, before CD4 decrease, and effective ART appear to improve CD4/CD8 ratio in long term viral suppression patients. [14]

CDC clinical stage was not associated with immune recovery in our study. In the European Collaborative Cohort study, children on clinical stage C were less likely to achieve a 20%

increase in CD4 z-score, compared to those who had cART initiated at clinical stage B or A. [26] In two studies conducted in Thailand, clinical CDC stage was not an independent predictor for reaching CD4 percentage > 25% after cART initiation. [19, 28]

In our study, higher baseline CD8 counts and lower baseline CD4/CD8 ratio were associated with worse immune recovery in univariate analysis. Baseline absolute CD8 cell counts and CD4/CD8 ratio has been described influencing the recovery of CD4/CD8 ratio and CD4 response in HIV-infected adults. [18, 30, 31]

No associations were found between baseline viral load and immune recovery in our population, which is consistent with other published data. [19] Longer duration of undetectable viral load was nearly significant to achieve a CD4/CD8 >1, with p value 0.2, probably due to the small size of the sample.

Moreover, in our study, ethnicity could not be considered as a predictor for immune response, as also reported in a study conducted in children in The Netherlands, despite initial differences in CD4 counts. [32] Similar results were found in adult population, observing a significantly lower CD4/CD8 ratio prior to commencing ART in Asian patients compared to Caucasian, but after adjustment, there was no significant difference between the cohorts in odds of achieving normal ratio. [33]

A limitation of this study is that, despite being the largest study to date in terms of the length of follow-up period of patients; in describing the immune reconstitution, the sample size is not representative of the entire Spanish cohort due to the fact that there were missing data for most patients in such a long follow-up period and, also due to the observational nature of the study. The second limitation is that CD4/CD8 ratio is an imperfect measure of immune reconstitution and immune activation and we did not consider other laboratory parameters that are now commonly used to describe immune reconstitution (quantification of CD31+CD45RA+CD4+ T cells) or immune activation (HLADR CD38 expression). The third limitation is that 30% of children received mono or dual therapy, which implies that these children started therapy in an earlier era of treatment when less potent antiretroviral therapy were available and this potential bias was not addressed.

Conclusion

This study showed the long-term immune recovery after 10 years of initiating and maintaining suppressive cART, nonetheless one third of patients did not achieve a CD4/CD8 ratio > 1, being associated with a lower CD4 nadir and receiving previously mono or dual therapy. All these data suggest that there is a difficulty in achieving immune recovery after severe immune deterioration, which highlights the importance of an early and effective treatment initiation. In addition, our observations showed a relationship between incomplete immune recovery and immune activation, despite maintained undetectable viral load, which requires longer follow up to elucidate its potential long term consequences.

Acknowledgments

CoRISpe Cohort Working Group

María José Mellado, Luis Escosa, Milagros García Hortelano, Talía Sainz (Hospital La Paz); María Isabel González- Tomé, Pablo Rojo, Daniel Blázquez, Cristina Epalza (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús Saavedra, Mar Santos, M^a Angeles Muñoz, Begoña Santiago, Santiago Jimenez de Ory, Itziar Carrasco, (Hospital Gregorio Marañón); Miguel Ángel Roa (Hospital de Móstoles); José Beceiro, María Penín (Hospital Príncipe

de Asturias, Alcalá de Henares); Jorge Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren Apilanez (Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, Bilbao); Elisa Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno Infantil, Las Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la Candelaria, Santa Cruz de Tenerife); Mónica Garzón, Vicente Román (Hospital de Lanzarote); María José Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf Neth, Lola Falcón (Hospital Virgen del Rocío, Sevilla); Pedro Terol (Hospital Virgen de la Macarena, Sevilla); Juan Luis Santos (Hospital Virgen de las Nieves, Granada); David Moreno (Hospital Carlos Haya, Málaga); Francisco Lendínez (Hospital de Torrecárdenas, Almería); Estrella Peromingo, María Montero (Hospital Puerta del Mar, Cádiz); Ana Grande (Complejo Hospitalario Universitario Infanta Cristina, Badajoz); Francisco José Romero (Complejo Hospitalario de Cáceres); Carlos Pérez (Hospital de Cabueñes, Gijón); María Martínez (Hospital Universitario Central de Asturias); Miguel Lillo (Hospital de Albacete); Begoña Losada (Hospital Virgen de la Salud, Toledo); Mercedes Herranz (Hospital Virgen del Camino, Pamplona); Matilde Bustillo, Carmelo Guerrero (Hospital Miguel Servet, Zaragoza); Pilar Collado (Hospital Clínico Lozano Blesa, Zaragoza); José Antonio Couceiro (Complejo Hospitalario de Pontevedra); Leticia Vila (Complejo Hospitalario Universitario La Coruña); Consuelo Calviño (Hospital Universitario Lucus Augusti de Lugo); Ana Isabel Piqueras, Rafael Bretón, Manuel Oltra, Eva López, Inmaculada Segarra (Hospital La Fe, Valencia); César Gavilán (Hospital San Juan de Alicante); Elena Montesinos (Hospital General de Valencia); Marta Dapena (Hospital de Castellón); Cristina Álvarez, Beatriz Jiménez (Hospital Marqués de Valdecilla, Santander); Ana Gloria Andrés (Hospital de León); Víctor Marugán, Carlos Ochoa (Hospital de Zamora); Santiago Alfayate, Ana Isabel Menasalvas (Hospital Virgen de la Arrixaca, Murcia); Yolanda Ruiz del Prado (Complejo Hospitalario San Millán-San Pedro, Logroño); Pere Soler-Palacín, Maria Antoinette Frick (Hospital Universitari Vall d'Hebron, Barcelona); Antonio Mur, Núria López (Hospital Universitari del Mar, Barcelona); María Méndez (Hospital Universitari Germans Trias i Pujol, Badalona); Lluís Mayol (Hospital Universitari Josep Trueta, Girona); Teresa Vallmanya (Hospital Universitari Arnau de Vilanova, Lleida); Olga Calavia (Hospital Universitari Joan XXIII, Tarragona); Lourdes García (Consorti Sanitari del Maresme, Mataró), Maite Coll (Hospital General de Granollers); Valentí Pineda (Corporació Sanitària Parc Taulí, Sabadell); Neus Rius (Hospital Universitari Sant Joan, Reus); Joaquín Dueñas (Hospital Son Espases, Mallorca); Clàudia Fortuny, Antoni Noguera-Julian (Hospital Sant Joan de Déu, Esplugues) and Paediatric HIV-BioBank integrated in the Spanish AIDS Research Network and collaborating Centers.

Author Contributions

Conceptualization: Sara Guillén, Luis Prieto, María Isabel González-Tomé, Pablo Rojo, María Luisa Navarro, María José Mellado, Luis Escosa, Talía Sainz, Laura Francisco, María Ángeles Muñoz-Fernández, José Tomás Ramos.

Data curation: Sara Guillén, Santiago Jiménez de Ory, Laura Francisco, José Tomás Ramos.

Formal analysis: Sara Guillén, Santiago Jiménez de Ory, José Tomás Ramos.

Funding acquisition: José Tomás Ramos.

Investigation: Sara Guillén, Luis Prieto, María Isabel González-Tomé, Pablo Rojo, María Luisa Navarro, María José Mellado, Luis Escosa, Talía Sainz, Laura Francisco, María Ángeles Muñoz-Fernández, José Tomás Ramos.

Methodology: Sara Guillén, Santiago Jiménez de Ory, José Tomás Ramos.

Project administration: Sara Guillén, José Tomás Ramos.

Resources: Sara Guillén, José Tomás Ramos.

Software: Sara Guillén, Santiago Jiménez de Ory, José Tomás Ramos.

Supervision: Sara Guillén, José Tomás Ramos.

Validation: Sara Guillén, José Tomás Ramos.

Visualization: Sara Guillén, José Tomás Ramos.

Writing – original draft: Sara Guillén, José Tomás Ramos.

Writing – review & editing: Sara Guillén, José Tomás Ramos.

References

1. Resino S, Resino R, Micheloud D, Gurbindo D, León JA, Ramos JT, et al. Long term effects of Highly active antiretroviral therapy in pretreated, vertically HIV type 1 infected children: 6 years of follow-up. *Clin Infect Dis* 2006; 42: 862–9. <https://doi.org/10.1086/500412>
2. Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woemer I, Babiker A, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. *Lancet* 2000; 355: 1331–2. [https://doi.org/10.1016/s0140-6736\(00\)02117-6](https://doi.org/10.1016/s0140-6736(00)02117-6) PMID: 10776748
3. Krogstad P, Patel K, Karalius B, Hazra R, Abzug MJ, Oleske J, et al. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents. *AIDS* 2015; 29: 683–693. <https://doi.org/10.1097/QAD.0000000000000598> PMID: 25849832
4. Corbeau P and Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. *Blood* 2011; 117: 5582–5590. <https://doi.org/10.1182/blood-2010-12-322453> PMID: 21403129
5. Sandgaard KS, Lewis J, Adams S, Klein N, Callard. Antiretroviral therapy increases thymic output in children with HIV. *AIDS* 2014; 28: 209–214. <https://doi.org/10.1097/QAD.0000000000000063>
6. Lewis J, Walker AS, Castro H, de Rossi A, Gibb DM, Giaquinto C, et al. Age and CD4 count at initiation of antiretroviral therapy in HI-infected children: effects on long term T–cell reconstitution. *J Infect Dis* 2012; 205: 548–556. <https://doi.org/10.1093/infdis/jir787>
7. De Rossi A, Walker AS, Klein N, de Forni D, King D, Gibb DM for the Paediatric European Network for Treatment of AIDS. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for treatment of AIDS (PENTA) 5 trial. *J Infect Dis* 2002; 186: 312–320. <https://doi.org/10.1086/341657> PMID: 12134227
8. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunological and virological outcomes. *J Acquir Immune Defic Syndr* 2011; 57: 165–173. <https://doi.org/10.1097/QAI.0b013e318215c7b1>
9. Van Rossum AMC, Scherpier HJ, Van Lochem EG, Pakker NG, Slieker WAT, Wolthers KC, et al. Therapeutic immune reconstitution in HIV-infected children is independent of their age and pre-treatment immune status. *AIDS* 2001; 15: 2267–2275. <https://doi.org/10.1097/00002030-200111230-00008>
10. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Response to combination antiretroviral therapy variation by age. *AIDS* 2008; 22: 1463–1473. <https://doi.org/10.1097/QAD.0b013e3282f88d02>
11. Resino S, Álvaro-Meca A, De José MI, Martín-Fontelos P, Gurbindo D, León JA, et al. Low immunological response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type-1- infected children with severe immunodeficiency. *Pediatr Infect Dis J* 2006; 25 (4): 365–368. <https://doi.org/10.1097/01.inf.0000207419.50016.5e>
12. Rainwater-Lovett K, Nkamba H, Mubiana-Mbwe M, Moore CB, Margolick J, Moss WJ. Changes in Cellular Immune Activation and Memory T-Cell Subsets in HIV-Infected Zambian Children Receiving HAART. *J Acquir Immune Defic Syndr* 2014; 67(5): 455–462. <https://doi.org/10.1097/QAI.0000000000000342> PMID: 25226208
13. Díaz L, Méndez Lagares G, Correa-Rocha R, Pacheco YM, Ferrando-Martínez S, Ruiz-Mateos E, et al. Detectable viral load aggravates features of CD8 T cell subsets in vertically HIV-infected children. *J Acquir Immune Defic Syndr* 2012; 60: 447–454. <https://doi.org/10.1097/QAI.0b013e318259254f>

14. Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutouilleau D, Agher R, Valantin MA, et al. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. *Clin Infect Dis* 2016; 62: 1297–1303. <https://doi.org/10.1093/cid/ciw076> PMID: 26908792
15. Sainz T, Serrano-Villar S, Díaz L, González-Tomé MI, Gurbindo MD, de José MI, et al. The CD4/CD8 ratio as a marker T cell activation, senescence and activation/exhaustion in treated HIV-infected children and Young adults. *AIDS* 2013; 27: 1513–1519. <https://doi.org/10.1097/QAD.0b013e32835faa72>
16. Serrano-Villar S, Gutiérrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad-Fernández M, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. *J infect* 2013 Jan; 66(1):57–66. <https://doi.org/10.1016/j.jinf.2012.09.013> PMID: 23046968
17. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. *Lancet HIV* 2015 Mar; 2(3):e98–106. [https://doi.org/10.1016/S2352-3018\(15\)00006-5](https://doi.org/10.1016/S2352-3018(15)00006-5) PMID: 26424550
18. Sauter R, Huang R, Ledergerber B, Battegay M, Bernasconi E, Cavassini M, et al. CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. *Medicine (Baltimore)* 2016 Oct; 95(42): e5094.
19. Collins IJ, Ngo-Giang-Huong N, Jourdain G, Chanta C, Puangsombat A, Kwanchaipanich, et al. Long term immune response in HIV infected children receiving highly active antiretroviral therapy in Thailand: outcomes at 7-years. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur, Malaysia, 2013. Abstract TUPE314.
20. Patel K, Hernán MA, Williams L, Seeger JD, McIntosh K, Van Dyke RB, et al. Long-term effects of Highly Active Antiretroviral therapy on CD4 cell evolution among children and adolescents infected with HIV: 5 years and counting. *Clin Infect Dis* 2008; 46: 1751–60. <https://doi.org/10.1086/587900>
21. De Biasi S, Bianchini E, Nasi M, Digaetano M, Gibellini I, Carnevale G, et al. Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. *AIDS* 2016 Nov 13; 30(17): 2599–2610. <https://doi.org/10.1097/QAD.0000000000001247> PMID: 27782963
22. Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. *J Int AIDS Soc* 2015 Jun 29; 18:20052. <https://doi.org/10.7448/IAS.18.1.20052> PMID: 26130226
23. Serrano-Villar S, Zhou Y, Rodgers AJ, Moreno S. Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients. *J Antimicrob Chemother* 2017 Jan; 72(1):235–239. <https://doi.org/10.1093/jac/dkw375> PMID: 27655859
24. Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, et al. Long term effects of protease inhibitor based combination therapy on CD4 T cell recovery in HIV-1 infected children and adolescents. *Lancet* 2003; 362: 2045–2051. [https://doi.org/10.1016/s0140-6736\(03\)15098-2](https://doi.org/10.1016/s0140-6736(03)15098-2)
25. Walker AS, Doerholt K, Sharland M, Gibb D for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. *AIDS* 2004; 18: 1915–1924. <https://doi.org/10.1097/00002030-200409240-00007>
26. European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is associated with age at initiation? *J Infect Dis* 2006; 193: 954–962. <https://doi.org/10.1086/500842>
27. Hainaut M, Ducarme M, Shandené L, Peltier CA, Marissens D, Zissis G, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. *Pediatr Infect Dis J* 2003; 22: 62–69. <https://doi.org/10.1097/01.inf.0000046024.57819.12> PMID: 12544411
28. Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunological recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor based highly active antiretroviral therapy. *Pediatr Infect Dis J* 2009; 28: 488–492.
29. Phongsamart W, Hansudewechakul R, Bunupuradah T, Klinbuayaem V, Teeraananchai S, Prasithsirikul W, et al. Long term outcomes of HIV-infected children in Thailand: the Thailand Pediatric HIV Observational Database. *Int J Infect Dis* 2014; 22: 19–24. <https://doi.org/10.1016/j.ijid.2013.12.011>
30. Caby F, writing Committee of the CD4/CD8 ratio working group of the French Hospital Database of HIV (FHDH-ANRS Co4). CD4/CD8 ratio restoration in long-term treated HIV-1-infected individuals: Incidence and determinants. *AIDS* 2017; 31: 1685–1695. <https://doi.org/10.1097/QAD.0000000000001533>
31. Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients

- on long-term suppressive antiretroviral therapy. *Clin Microbiol Infect* 2012 May; 18(5):449–58. <https://doi.org/10.1111/j.1469-0691.2011.03650.x> PMID: 21919996
32. Cohen S, Van Bilsen WPH, Smit C, Fraaij PLA, Warris A, Kuijpers TW, et al. Country of birth does not influence long term clinical, virologic and immunological outcome of HIV-infected children living in the Netherlands: a cohort study comparing children born in the Netherlands with children born in sub-Saharan Africa. *J Acquir Immune Defic Syndr* 2015; 68: 178–185. <https://doi.org/10.1097/QAI.0000000000000431>
 33. Petoumenos K, Choi JY, Hoy J, Kiertiburanakul S, Ng O Tek, Boyd M, et al. CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. *Antivir Ther* 2017; 22: 659–668. <https://doi.org/10.3851/IMP3155> PMID: 28291735